Extended release huperzine for the treatment of idiopathic epilepsy in dogs – a Case Report

Huperzine is a naturally occurring alkaloid derived from the Chinese clubmoss <i>Huperzia serrata</i>. It is a potent acetylcholinesterase inhibitor, among other properties, and has demonstrated protection against induced seizures in a mouse model of Dravet's syndrome as well as nerve-agent induced seizures and is being explored as a novel anticonvulsant in a human clinical trial for focal impaired awareness seizures. It is also being explored as a treatment for Alzheimer's, via neuroprotective effects and an ability to ameliorate neuroinflammation. Here we present a case series of 6 dogs with idiopathic epilepsy treated with huperzine to investigate this potential novel anticonvulsant. Despite a 50% drop out rate over the course of the study due to various causes including unexplained death, humane euthanasia and systemic disease, huperzine was generally well tolerated and showed some positive effects on demeanor. This study highlights the need for more research to investigate its efficacy as a novel antiepileptic medication in dogs.

Authors

Publication Details

Journal
Frontiers in Veterinary Science
Published
2025-03-13
DOI
https://doi.org/10.3389/fvets.2025.1518379
Citations
4
Primary Topic
Cholinesterase and Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
5.58
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Extended release huperzine for the treatment of idiopathic epilepsy in dogs – a Case Report

Sam Long, Ken Grant
4 citations
Frontiers in Veterinary Science
Cholinesterase and Neurodegenerative Diseases
5.58
article

Extended release huperzine for the treatment of idiopathic epilepsy in dogs – a Case Report

Sam Long, Ken Grant
article en
4 citations

Abstract

Huperzine is a naturally occurring alkaloid derived from the Chinese clubmoss <i>Huperzia serrata</i>. It is a potent acetylcholinesterase inhibitor, among other properties, and has demonstrated protection against induced seizures in a mouse model of Dravet's syndrome as well as nerve-agent induced seizures and is being explored as a novel anticonvulsant in a human clinical trial for focal impaired awareness seizures. It is also being explored as a treatment for Alzheimer's, via neuroprotective effects and an ability to ameliorate neuroinflammation. Here we present a case series of 6 dogs with idiopathic epilepsy treated with huperzine to investigate this potential novel anticonvulsant. Despite a 50% drop out rate over the course of the study due to various causes including unexplained death, humane euthanasia and systemic disease, huperzine was generally well tolerated and showed some positive effects on demeanor. This study highlights the need for more research to investigate its efficacy as a novel antiepileptic medication in dogs.

Frontiers in Veterinary ScienceVol. 12
Good health and well-being
Openalex Percentile: Top 5%
Cholinesterase and Neurodegenerative Diseases
5.58
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Extended release huperzine for the treatment of idiopathic epilepsy in dogs – a Case Report — Sam Long, Ken Grant · Frontiers in Veterinary Science (2025) | TGRS Research Map | TGRS